Dominique Demolle, CEO of Cognivia, is set to deliver a captivating presentation at the upcoming DPharm conference which is scheduled for…
What the FDA’s Final Guidance on Covariates Means for Fighting the Placebo Response in RCTs: Our Article Published in ACRP Journal
The recently released final guidance by the U.S. Food & Drug Administration (FDA) on “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products” introduces a new framework that is poised to transform the way statistical analyses are conducted in RCTs.
Covariate Adjustment in Randomized Clinical Trials Based on Latest FDA Guidance: Application to composite covariates
In May 2023, the FDA has unveiled its definitive guidance titled “Adjusting for Covariates in Randomized Clinical Trials (RCT) for Drugs…
Patient adherence remains a significant challenge in clinical research and medical practice, affecting drug development, healthcare costs, and…
Cognivia expands its portfolio of predictive solutions introducing Compl-AI©™, an innovative solution that predicts the risk of patient nonadherence & dropout
Compl-AI is a predictive tool that helps clinical trial sponsors optimize patient recruitment and engagement strategies. Nonadherence in clinical trials and high rates of dropout make efficacy and safety more difficult to determine.
2022 was a year of remarkable success for Cognivia.
Thank you to our team, partners and clients for your continued support! Here are highlights from this year – from exciting company updates to thought leadership articles.